Mounting evidence points to both arterial pulsatility and pump shear as factors that may be
responsible for the high incidence of nonsurgical bleeding events observed in patients with …

This study by Kang and co-authors 1 investigates the effect of decreasing HeartMate II
(Thoratec Corporation, Pleasanton, Calif) left ventricular assist device (LVAD; Figure 1) …

The extent of hematologic effects of the new continuous flow left ventricular assist devices
(CF-LVAD) has not been studied. Recent clinical studies have demonstrated that hemolysis …

The management of continuous-flow left ventricular assist devices (LVADs) continues to
evolve. Benefits of pulsatile versus nonpulsatile mechanical circulatory support remain an …

Non-surgical bleeding is the most frequent adverse event in patients with a continuous-flow
left ventricular assist device (CF-LVAD). Bleeding is a major source of morbidity and an …

Background Supraphysiologic shear stress from continuous-flow left ventricular assist
devices (LVADs) accelerates von Willebrand factor (vWF) degradation and predisposes …

Background Bleeding and thromboembolic events are identified complications in patients
supported with newer centrifugal continuous-flow left ventricular assist devices (cfLVADs) …

Continuous-flow (CF) left ventricular assist devices (LVADs) have revolutionized the
management of patients with end-stage heart failure, increasing access and improving …

Over the past two decades, left ventricular assist device (LVAD) support has emerged as
standard therapy for adult patients with advanced, life-threatening heart failure …

The use of ventricular assist devices (VADs) as a treatment for end-stage heart failure has
increased substantially in the past 5 years, due largely to the introduction and now proven …